What Researchers Did
A retrospective comparative study investigated the impact of adjunctive hyperbaric oxygen therapy (HBOT) on mortality in patients with Fournier's gangrene.
What They Found
Out of 197 patients, 118 received standard treatment (control group) and 79 received standard treatment plus HBOT. Mortality in the control group was 28.8% (34 out of 118 patients), significantly higher than the 3.7% mortality (3 out of 77 patients) observed in the HBOT group (P < 0.001).
What This Means for Canadian Patients
For Canadian patients diagnosed with Fournier's gangrene, this study suggests that adding hyperbaric oxygen therapy to standard care could substantially improve survival rates. This adjunctive treatment may offer a significant benefit in reducing the severe risk of mortality associated with this aggressive infection.
Canadian Relevance
This study was not conducted in Canada and does not have direct Canadian relevance.
Study Limitations
As a retrospective comparative study, it is subject to inherent biases and confounding factors that may affect the generalizability of the findings.